188 related articles for article (PubMed ID: 19844963)
1. Use of ion mobility mass spectrometry and a collision cross-section algorithm to study an organometallic ruthenium anticancer complex and its adducts with a DNA oligonucleotide.
Williams JP; Lough JA; Campuzano I; Richardson K; Sadler PJ
Rapid Commun Mass Spectrom; 2009 Nov; 23(22):3563-9. PubMed ID: 19844963
[TBL] [Abstract][Full Text] [Related]
2. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate.
Wang F; Xu J; Habtemariam A; Bella J; Sadler PJ
J Am Chem Soc; 2005 Dec; 127(50):17734-43. PubMed ID: 16351102
[TBL] [Abstract][Full Text] [Related]
3. Identifying drug metallation sites on peptides using electron transfer dissociation (ETD), collision induced dissociation (CID) and ion mobility-mass spectrometry (IM-MS).
Williams JP; Brown JM; Campuzano I; Sadler PJ
Chem Commun (Camb); 2010 Aug; 46(30):5458-60. PubMed ID: 20505878
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.
Wu K; Luo Q; Hu W; Li X; Wang F; Xiong S; Sadler PJ
Metallomics; 2012 Feb; 4(2):139-48. PubMed ID: 22262368
[TBL] [Abstract][Full Text] [Related]
5. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes.
Liu HK; Wang F; Parkinson JA; Bella J; Sadler PJ
Chemistry; 2006 Aug; 12(23):6151-65. PubMed ID: 16807967
[TBL] [Abstract][Full Text] [Related]
6. Isomer separation and gas-phase configurations of organoruthenium anticancer complexes: ion mobility mass spectrometry and modeling.
Williams JP; Bugarcic T; Habtemariam A; Giles K; Campuzano I; Rodger PM; Sadler PJ
J Am Soc Mass Spectrom; 2009 Jun; 20(6):1119-22. PubMed ID: 19297193
[TBL] [Abstract][Full Text] [Related]
7. Binding of DNA purine sites to dirhodium compounds probed by mass spectrometry.
Chifotides HT; Koomen JM; Kang M; Tichy SE; Dunbar KR; Russell DH
Inorg Chem; 2004 Oct; 43(20):6177-87. PubMed ID: 15446862
[TBL] [Abstract][Full Text] [Related]
8. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
[TBL] [Abstract][Full Text] [Related]
9. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
Groessl M; Hartinger CG; Dyson PJ; Keppler BK
J Inorg Biochem; 2008; 102(5-6):1060-5. PubMed ID: 18222004
[TBL] [Abstract][Full Text] [Related]
10. Energetics, conformation, and recognition of DNA duplexes modified by monodentate Ru(II) complexes containing terphenyl arenes.
Novakova O; Malina J; Suchankova T; Kasparkova J; Bugarcic T; Sadler PJ; Brabec V
Chemistry; 2010 May; 16(19):5744-54. PubMed ID: 20376825
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
[TBL] [Abstract][Full Text] [Related]
12. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity.
Hartinger CG; Casini A; Duhot C; Tsybin YO; Messori L; Dyson PJ
J Inorg Biochem; 2008 Dec; 102(12):2136-41. PubMed ID: 18834634
[TBL] [Abstract][Full Text] [Related]
13. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
14. Identification and discrimination of binding sites of an organoruthenium anticancer complex to single-stranded oligonucleotides by mass spectrometry.
Liu S; Wu K; Zheng W; Zhao Y; Luo Q; Xiong S; Wang F
Analyst; 2014 Sep; 139(18):4491-6. PubMed ID: 25028701
[TBL] [Abstract][Full Text] [Related]
15. 106Ru radiolabelling of the antitumour complex [(eta6-fluorene)Ru(en)Cl]PF6.
Hoeschele JD; Habtemariam A; Muir J; Sadler PJ
Dalton Trans; 2007 Nov; (43):4974-9. PubMed ID: 17992282
[TBL] [Abstract][Full Text] [Related]
16. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
17. Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.
Wang F; Xu J; Wu K; Weidt SK; Mackay CL; Langridge-Smith PR; Sadler PJ
Dalton Trans; 2013 Mar; 42(9):3188-95. PubMed ID: 23076358
[TBL] [Abstract][Full Text] [Related]
18. DNA structural distortions induced by ruthenium-arene anticancer compounds.
Gossens C; Tavernelli I; Rothlisberger U
J Am Chem Soc; 2008 Aug; 130(33):10921-8. PubMed ID: 18651736
[TBL] [Abstract][Full Text] [Related]
19. Electrospray ionization mass spectrometry of covalent ligand-oligonucleotide adducts: evidence for specific duplex ion formation.
Wickham G; Iannitti P; Boschenok J; Sheil MM
Rapid Commun Mass Spectrom; 1995; Spec No():S197-203. PubMed ID: 8829481
[TBL] [Abstract][Full Text] [Related]
20. High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides.
Egger AE; Hartinger CG; Ben Hamidane H; Tsybin YO; Keppler BK; Dyson PJ
Inorg Chem; 2008 Nov; 47(22):10626-33. PubMed ID: 18947179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
